Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy

(2011) Dongho Kim et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Renal Failure under Dasatinib Therapy

(2010) Sultan Ozkurt et al.   RENAL FAILURE

Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?

(2009) Mark Goldblatt et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

(2009) Kimmo Porkka et al.   CANCER

New dosing schedules of dasatinib for CML and adverse event management

(2009) Siu-Fun Wong   Journal of Hematology & Oncology

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

(2009) David Masiello et al.   Journal of Hematology & Oncology

Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature

(2009) Anat Gafter-Gvili et al.   LEUKEMIA RESEARCH

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

(2009) Kevin Kelly et al.   Targeted Oncology

Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss

(2008) Helene François et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

(2008) Hugues de Lavallade et al.   BRITISH JOURNAL OF HAEMATOLOGY

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Role of platelet-derived growth factors in physiology and medicine

(2008) J. Andrae et al.   GENES & DEVELOPMENT

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure

(2008) M. Sonmez et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia

(2008) Sarah A. Holstein et al.   LEUKEMIA RESEARCH